Clinical applications involving CNS gene transfer

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Central nervous system (CNS) diseases present significant treatment challenges due to the blood-brain barrier and difficulties with repeated drug administration.
• Traditional pharmacological methods are often limited in their ability to effectively target and treat CNS disorders.

Purpose of the Study:

• To explore the historical development, current status, and future prospects of gene therapy for central nervous system disorders.
• To focus on clinical trials employing adeno-associated virus (AAV) and lentiviral vectors for CNS gene therapy.

Main Methods:

• Review of past, current, and future gene therapy strategies for CNS disorders.
• Focus on clinical trials utilizing viral vector gene transfer, specifically adeno-associated virus and lentiviral vectors.
• Discussion of gene replacement and disease-modifying protein delivery approaches.

Main Results:

• Gene therapy, particularly viral vector gene transfer, offers a method for permanent therapeutic protein delivery to the CNS after a single administration.
• Gene therapy approaches for CNS disorders have evolved significantly over the last two decades, becoming safer and potentially more effective.
• While a definitive breakthrough treatment remains elusive, current strategies show considerable promise.

Conclusions:

• Viral vector gene transfer represents a viable strategy for overcoming challenges in treating CNS diseases.
• Ongoing advancements in gene therapy, utilizing vectors like AAV and lentivirus, are improving treatment safety and efficacy for neurological disorders.
• The field is progressing towards more effective therapeutic solutions for previously intractable CNS conditions.